Table 1

 Patient characteristics and concomitant drug treatment at entry

VariableFirst year (n = 820)Years 2–4 (n = 253)Entire cohort (n = 1073)
Values are n (%) or mean, as indicated.
*Reported drug treatment during the first three months of follow up.
DAS, disease activity score; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; NSAID, non-steroidal anti-inflammatory drug.
Female sex627 (76.5%)195 (77.1%)822 (76.6%)
Age (years), mean52.351.052.0
HAQ, mean score1.641.501.62
    Missing33 (4.0%)40 (15.8%)73 (6.8%)
DAS 28, mean6.05.75.9
    Missing56 (6.8%)53 (20.9%)109 (10.2%)
C reactive protein (mg/l), mean483645
    Missing28 (3.4%)38 (15.0%)66 (6.2%)
ESR (mm/h), mean473945
    Missing39 (4.8%)47 (18.6%)86 (8.0%)
Doctor’s global assessment
    No disease activity2 (0.2%)4 (1.6%)6 (0.6%)
    Low disease activity47 (5.7%)18 (7.1%)65 (6.1%)
    Moderate disease activity338 (41.2%)91 (36.0%)429 (40.0%)
    High disease activity379 (46.2%)97 (38.3%)476 (44.4%)
    Maximum disease activity18 (2.2%)5 (2.0%)23 (2.1%)
    Missing36 (4.4%)38 (15.0%)74 (6.9%)
Concomitant drug treatment*
    DMARD none377 (46.0%)110 (43.5%)487 (45.4%)
        One372 (45.4%)97 (38.3%)469 (43.7%)
        Two60 (7.3%)12 (4.7%)72 (6.7%)
        Three2 (0.2%)2 (0.8%)4 (0.4%)
        Methotrexate339 (41.3%)91 (36.0%)430 (40.1%)
        Sulfasalazine46 (5.6%)10 (4.0%)56 (5.2%)
        Ciclosporin36 (4.4%)9 (3.6%)45 (4.2%)
        Azathioprine21 (2.6%)4 (1.6%)25 (2.3%)
    Chloroquine/hydroxychloroquine18 (2.2%)6 (2.4%)24 (2.2%)
        Reumacon® (CPH 82)16 (2.0%)1 (0.4%)17 (1.6%)
        Sodium aurothiomalate7 (0.9%)07 (0.7%)
        Auranofin5 (0.6%)05 (0.5%)
        Other DMARD10 (1.2%)6 (2.4%)16 (1.5%)
        Missing9 (1.1%)32 (12.7%)41 (3.8%)
    Corticosteroids779 (95.0%)242 (95.7%)1021 (95.2%)
    Non-aspirin NSAIDs779 (95.0%)242 (95.7%)1021 (95.2%)
    Other analgesics738 (90.0%)231 (91.3%)969 (90.3%)